Amway China announced its commitment to a five-year project that will upgrade the basic infrastructure and production facilities in its production base in Guangzhou. The $87 million investment is expected to strengthen the company’s existing R&D capabilities, promote cooperation with other brands within the Chinese health industry and leverage the region’s advantages within the biomedical industry.
“The investment this time round would help to promote high quality development in Amway’s manufacturing and supply chain, promote the integration of the enterprise domestically and [internationally], as well as contribute to the modernization of China’s industry,” said Amway Chief Executive Officer Milind Pant.
Amway China also announced plans to build its own organic farms to support and study the use of agricultural technique innovations, cultivate new botanical species and include Traditional Chinese Medicine as part of its new product development and research process.
These investments are part of a larger strategy by Amway China to prepare for its personalized nutrition business, which began with Amway’s strategic partnership with South Korea-based Holzapfel Effective Microbes (HEM). In 2022, Amway Korea launched a precision probiotics service.